What is the minimal input required for MRD detection?

Sample requirements depend on the anticipated frequency of residual clones and the sensitivity needed for the study. Creative Biolabs can successfully perform ultra-sensitive MRD analysis with as few as tens of thousands of T cells, thanks to our optimized low-input library preparation protocols. However, for maximal confidence and deeper repertoire coverage, we recommend discussing your specific sample type, cell source, and experimental goals with our team so we can advise the optimal input range for your project.

Can frozen or low-viability samples be used?

Yes. Creative Biolabs has extensive experience working with cryopreserved PBMCs, frozen tissue-derived lymphocytes, and samples of variable viability. Our protocols are adapted to maximize nucleic acid recovery and minimize bias introduced by sample quality. While high-viability samples typically yield the most comprehensive repertoires, our workflows are designed to ensure reliable MRD quantification even when starting material is limited or partially compromised.

Can MRD be monitored over multiple time points?

Absolutely. Creative Biolabs' pipeline is specifically structured to support longitudinal studies, allowing researchers to follow the persistence, expansion, or decline of specific TCR clonotypes across multiple time points. High reproducibility across runs ensures that clonal tracking reflects true biological dynamics rather than technical noise, making it possible to confidently study clonal kinetics in long-term projects.

Are results compatible with other TCR studies?

Yes. Processed clonotype tables and IMGT-aligned sequences can be integrated with other repertoire datasets, enabling comparative or meta-analyses.

TCR Repertoire Analysis Service for Minimal Residual Disease Quantiﬁcation

Platform Workflow Features Testimonials FAQ

Minimal residual disease (MRD) refers to the small number of T cells or leukemic clones that remain in a sample after experimental treatment, immune challenge, or disease intervention. Even at extremely low abundance, these residual clonotypes can provide critical insights into immune dynamics, clonal persistence, and cellular responses.

At Creative Biolabs, our TCR Repertoire Analysis Service for MRD Quantification enables researchers to detect and quantify extremely rare TCR sequences with unparalleled sensitivity and reproducibility. By leveraging high-throughput sequencing, specialized enrichment, and advanced computational analysis, Creative Biolabs empowers laboratories to track clonal persistence, assess immune reconstitution, and explore subtle repertoire changes in basic research settings.

Technical Platform: Precision Meets Sensitivity

Creative Biolabs' MRD platform integrates next-generation sequencing (NGS) with targeted TCR enrichment and error-corrected library construction. Key platform features include:

High-Sensitivity Sequencing

Ultra-deep coverage ensures that even clonotypes present at frequencies as low as 0.001% can be reliably detected.

Library Preparation

By minimizing PCR bias, specific molecular tags enable accurate quantification of rare TCRs.

Targeted Clonotype Panels

Depending on research goals, panels can be customized to focus on specific V(D)J rearrangements or expanded to capture the full TCR repertoire.

Robust Bioinformatics Pipeline

Creative Biolabs' analysis workflow includes sequence alignment against IMGT to identify V and J gene segments, clonotype assembly, error correction, and sensitive MRD quantification.

This combination of technology ensures that MRD assessment is both quantitative and high-confidence, providing researchers with actionable insights into residual clonotype dynamics.

Stepwise Research Workflow

Fig.1 Specimen Acquisition. (Creative Biolabs AI)

01 Sample Collection and Preprocessing

Creative Biolabs accepts a variety of sample types, including PBMCs, lymphoid tissues, and cell suspensions. All samples undergo rigorous quality control, including viability checks and initial T cell enumeration. For MRD applications, proper sample handling is critical to prevent loss of rare clonotypes. Creative Biolabs' protocols are optimized for low-input or cryopreserved samples, ensuring reproducible detection even when cell numbers are limited.

Inquire with us

Fig.2 T-Cell Receptor Enrichment. (Creative Biolabs AI)

02 TCR Enrichment and Target Selection

Given the extremely low frequency of residual clones, enrichment strategies are often employed. Creative Biolabs uses:

Targeted PCR or multiplex primer sets to amplify specific V(D)J rearrangements.
Optional antigen-specific or phenotypic sorting if MRD assessment is focused on a particular T cell subset.

These steps enhance the representation of rare clonotypes while minimizing background from abundant irrelevant sequences.

Inquire with us

Fig.3 Preparation of Sequencing Libraries. (Creative Biolabs AI)

03 Library Preparation

Extracted nucleic acids are processed using library preparation to accurately capture each unique TCR molecule. High-fidelity amplification and adapter ligation are performed under stringent QC. Libraries are quantified, size-verified, and assessed for complexity to ensure sufficient depth for MRD detection.

Inquire with us

Fig.4 Large-Scale Sequencing Performance. (Creative Biolabs AI)

04 High-Throughput Sequencing

Creative Biolabs utilizes sequencing platforms with deep sequencing strategies to achieve comprehensive coverage of the target repertoire. Sequencing depth is adjusted based on sample type, input material, and the desired sensitivity for residual clone detection.

Inquire with us

Fig.5 Bioinformatic Processing. (Creative Biolabs AI)

05 Computational Analysis and Clonotype Identification

Raw reads are quality-filtered, and sequences are aligned against the IMGT database to identify rearranged V and J gene segments. Clonotypes are assembled and quantified, with error correction applied to minimize false positives. Our MRD-specific bioinformatics workflow outputs:

Absolute and relative abundance of residual clonotypes.
Tracking of persistent or expanded clones across time points.
Diversity metrics and clonal distribution plots.
Comparative analysis between experimental conditions, enabling detection of subtle shifts in the repertoire.

Inquire with us

Why Choose Creative Biolabs: Advantages for MRD Analysis

Ultra-Sensitive Detection

Capable of identifying TCR clonotypes at frequencies below 0.01%, making it suitable for rare residual populations.

Quantitative Accuracy

Library preparation ensures precise measurement of each clone's abundance.

IMGT-Standardized Annotation

Aligning sequences to the IMGT database guarantees reproducible and internationally recognized gene segment identification.

Flexible and Scalable

Works with small pilot studies as well as large longitudinal experiments.

Integrated Workflow

From sample handling to advanced computational analysis, Creative Biolabs performs all steps in-house for consistent quality control.

Research-Oriented

Designed exclusively for basic research applications; results focus on repertoire biology and clonal dynamics rather than clinical interpretation.

Ask about our features!

Customer Feedback

"Creative Biolabs' MRD service allowed us to quantify residual T cell clonotypes that we couldn't detect with conventional sequencing. The sensitivity and clarity of the report were outstanding and immediately useful for our research."

— Head of Oncology Programs, Research Institute

"The combination of deep sequencing and Creative Biolabs' analytical pipeline gave us confidence in detecting rare clones across multiple time points. Their team is responsive and clearly understands the needs of basic immunology research."

— Senior Scientist, Oncology Translational Center

Discover client feedback!

Minimal residual disease represents an opportunity to study rare clonotypes and immune persistence in detail. Creative Biolabs' TCR Repertoire Analysis Service for MRD Quantification combines deep sequencing, rigorous bioinformatics, and research-focused interpretive reporting to give scientists a high-confidence view of residual T cell populations. Our team is here to support your project every step of the way.

Frequently Asked Questions

Q: What is the minimal input required for MRD detection?
A: Sample requirements depend on the anticipated frequency of residual clones and the sensitivity needed for the study. Creative Biolabs can successfully perform ultra-sensitive MRD analysis with as few as tens of thousands of T cells, thanks to our optimized low-input library preparation protocols. However, for maximal confidence and deeper repertoire coverage, we recommend discussing your specific sample type, cell source, and experimental goals with our team so we can advise the optimal input range for your project.
Q: Can frozen or low-viability samples be used?
A: Yes. Creative Biolabs has extensive experience working with cryopreserved PBMCs, frozen tissue-derived lymphocytes, and samples of variable viability. Our protocols are adapted to maximize nucleic acid recovery and minimize bias introduced by sample quality. While high-viability samples typically yield the most comprehensive repertoires, our workflows are designed to ensure reliable MRD quantification even when starting material is limited or partially compromised.
Q: Can MRD be monitored over multiple time points?
A: Absolutely. Creative Biolabs' pipeline is specifically structured to support longitudinal studies, allowing researchers to follow the persistence, expansion, or decline of specific TCR clonotypes across multiple time points. High reproducibility across runs ensures that clonal tracking reflects true biological dynamics rather than technical noise, making it possible to confidently study clonal kinetics in long-term projects.
Q: Are results compatible with other TCR studies?
A: Yes. Processed clonotype tables and IMGT-aligned sequences can be integrated with other repertoire datasets, enabling comparative or meta-analyses.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: